With the campaign, Highlights REAL, they are spotlighting the everyday experiences of advanced prostate cancer patients and ...

Transdermal oestradiol patches are non-inferior to luteinising hormone-releasing hormone agonists for metastasis free survival in locally advanced prostate cancer, a study shows.

A 40-year-old dad received a shock cancer diagnosis after simply experiencing back pain, he is now raising awareness among ...

Hyderabad is witnessing a rise in advanced-stage prostate cancer due to low screening rates and lifestyle factors. Experts ...

The Prostate Cancer Foundation (PCF) today announced the launch of the Hästens-PCF Global Health Award, a new initiative designed to advance equitable prostate cancer detection, diagnosis, and care in ...

The main advantage of proton therapy is its precision. Protons deposit most of their energy directly in the tumor with little ...

For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to luteinizing ...

A recent study published in The New England Journal of Medicine found that transdermal estradiol (tE2) therapy was ...

Mordor Intelligence has published a new report on the prostate cancer market, offering a comprehensive analysis of trends, growth drivers, and future projections.

The campaign for better prostate cancer awareness has provoked important questions about the lack of testing and screening. Why are men dying unnecessarily?

New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

A common diabetes drug may mimic one key effect of exercise in prostate cancer patients. Researchers found metformin boosts an “exercise molecule” linked to appetite and weight control, even in those ...